MedTrace Logo

Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)

NCT00770289 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 851

Last updated 2012-08-31

Study results available
· View outcomes & findings →

Summary

Tools known as 'depression scales 'are widely used as assessments to evaluate a patient's response to treatment. The purpose of this study is the evaluation of the remission rates for patients with MDD. The evaluation will involve the use of HAM-D 17, and HAM-D 7 questionnaires and the comparison of those questionnaires.

Conditions

Interventions

OTHER

Cohort

Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Greece

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00770289 on ClinicalTrials.gov